ARTICLE | Clinical News
LAX-101: Began Phase III trial
December 18, 2000 8:00 AM UTC
Amarin Corp. plc (AMRN), Ely, U.K. Product: LAX-101 Business: Neurological Therapeutic category: Neuroprotectant, Apoptosis Target: Phospholipase A2 and caspases Description: Inhibitor of phospholi...